CLINICAL TRIALS PROFILE FOR SODIUM FERRIC GLUCONATE COMPLEX
✉ Email this page to a colleague
All Clinical Trials for sodium ferric gluconate complex
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00223938 ↗ | Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients. | Terminated | Sanofi | Phase 4 | 2003-12-30 | This is a phase 4 clinical investigation of the efficacy and safety of Ferrlecit in the maintenance of iron stores and serum hemoglobin concentration in hemodialysis patients receiving Erythropoietin. |
| NCT00223938 ↗ | Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients. | Terminated | Watson Pharmaceuticals | Phase 4 | 2003-12-30 | This is a phase 4 clinical investigation of the efficacy and safety of Ferrlecit in the maintenance of iron stores and serum hemoglobin concentration in hemodialysis patients receiving Erythropoietin. |
| NCT00354692 ↗ | Effect of Two Iron Preparations on Protein in the Urine | Completed | Watson Pharmaceuticals | Phase 4 | 2006-06-01 | This pilot study will compare the effects of sodium ferric gluconate complex and iron sucrose on urine concentrations of various chemicals including protein |
| NCT00534144 ↗ | Comparison Between Effects of Two Iron Preparations on Protein in the Urine | Completed | Watson Pharmaceuticals | Phase 1 | 2007-09-01 | This study will compare the effects of sodium ferric gluconate complex and iron sucrose on urine concentrations of various chemicals including protein |
| NCT00661999 ↗ | Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer | Completed | National Cancer Institute (NCI) | Phase 3 | 2006-01-01 | RATIONALE: Darbepoetin alfa may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues. It is not yet known whether giving darbepoetin alfa (DA) together with intravenous iron or oral iron is more effective than giving darbepoetin alfa together with a placebo in treating anemia caused by chemotherapy. PURPOSE: This randomized phase III trial is studying giving darbepoetin alfa together with iron to see how well it works compared with giving darbepoetin alfa together with a placebo in treating anemia caused by chemotherapy in patients with cancer. |
| NCT00661999 ↗ | Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer | Completed | Mayo Clinic | Phase 3 | 2006-01-01 | RATIONALE: Darbepoetin alfa may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues. It is not yet known whether giving darbepoetin alfa (DA) together with intravenous iron or oral iron is more effective than giving darbepoetin alfa together with a placebo in treating anemia caused by chemotherapy. PURPOSE: This randomized phase III trial is studying giving darbepoetin alfa together with iron to see how well it works compared with giving darbepoetin alfa together with a placebo in treating anemia caused by chemotherapy in patients with cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for sodium ferric gluconate complex
Condition Name
Clinical Trial Locations for sodium ferric gluconate complex
Trials by Country
Clinical Trial Progress for sodium ferric gluconate complex
Clinical Trial Phase
Clinical Trial Sponsors for sodium ferric gluconate complex
Sponsor Name
